|
Market Closed -
Nasdaq
16:00:00 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 50.04 USD | +1.60% |
|
-2.93% | -4.58% |
| 10-19 | CRISPR Therapeutics Names A.J. Silver as New Chief Financial Officer | MT |
| 10-16 | Crispr Therapeutics Insider Sold Shares Worth $720,373, According to a Recent SEC Filing | MT |
| Market Cap | 4.84B 4.31B 4B 3.63B 6.82B 459B 6.93B 47.92B 18.84B 240B 18.15B 17.77B 766B | P/E 2026 * |
-11.5x | P/E 2027 * | -15x |
|---|---|---|---|---|---|
| Enterprise Value | 3.31B 2.95B 2.73B 2.48B 4.66B 314B 4.74B 32.76B 12.88B 164B 12.41B 12.15B 524B | EV / Sales 2026 * |
81.8x | EV / Sales 2027 * | 24.3x |
| Free-Float |
94.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CRSP | Delayed | |
CBOE
| CRSP | Real-time | |
|
Tradegate
| 1CG | Real-time | |
|
Boerse Muenchen
| 1CG | Real-time | |
|
Mexican S.E.
| CRSP N | End-of-day quote | |
|
Börse Stuttgart
| 1CG | Delayed | |
|
Deutsche Boerse AG
| 1CG | Delayed | |
|
London S.E.
| 0VRQ | Delayed | |
|
Berne S.E.
| 1CG | End-of-day quote |
Last Transcript: CRISPR Therapeutics AG
| 1 day | +1.60% | ||
| 1 week | -2.93% | ||
| Current month | -9.54% | ||
| 1 month | -11.53% | ||
| 3 months | +4.73% | ||
| 6 months | -13.71% | ||
| Current year | -4.58% |
| 1 week | 48.91 |  | 52.37 |
| 1 month | 48.91 | | 60.72 |
| Current year | 44.12 | | 63.45 |
| 1 year | 44.12 | | 75.06 |
| 3 years | 30.04 | | 91.1 |
| 5 years | 30.04 | | 99.45 |
| 10 years | 11.63 | | 220.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 47 | 2017-11-30 |
Raju Prasad
DFI | Director of Finance/CFO | 42 | 2023-03-13 |
Naimish Patel
CTO | Chief Tech/Sci/R&D Officer | - | 2024-05-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Simeon George
BRD | Director/Board Member | 49 | 2015-04-28 |
Ali Behbahani
BRD | Director/Board Member | 49 | 2015-03-31 |
Samarth Kulkarni
CHM | Chairman | 47 | 2023-09-14 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/14/26 | Sell | General Counsel | -1,040 | 0.0011% | ||
| 10/14/26 | Exercice | Director | 74,514 | 0.0771% | ||
| 10/14/26 | Sell | Chief Executive Officer | -4,098 | 0.0042% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.60% | -2.93% | -27.64% | +25.79% | 4.76B | |
| +1.52% | -7.19% | +51.66% | +69.99% | 65B | |
| +1.52% | +6.83% | +10.77% | +79.30% | 51.2B | |
| +0.30% | -0.46% | +2.53% | +61.89% | 51.19B | |
| -0.38% | +1.40% | +29.98% | +42.37% | 43.93B | |
| +0.30% | +5.64% | +16.99% | +133.30% | 41.96B | |
| +2.35% | -6.08% | +236.69% | +528.10% | 38.14B | |
| +2.16% | +9.87% | +18.92% | +59.70% | 33.24B | |
| +1.60% | +2.21% | +21.34% | +28.00% | 22.5B | |
| +1.71% | -6.92% | -15.15% | -4.32% | 22.03B | |
| Average | +1.27% | -0.46% | +34.61% | +102.41% | 37.4B | |
| Weighted average by Cap. | +1.15% | +0.04% | +42.09% | +112.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 40.44M 36.05M 33.39M 30.36M 56.97M 3.83B 57.91M 401M 157M 2B 152M 149M 6.41B | 151M 135M 125M 114M 213M 14.33B 217M 1.5B 589M 7.49B 567M 555M 23.95B |
| Net income | -432M -385M -357M -325M -609M -40.99B -619M -4.28B -1.68B -21.42B -1.62B -1.59B -68.49B | -342M -305M -282M -257M -482M -32.42B -490M -3.39B -1.33B -16.94B -1.28B -1.26B -54.17B |
| Net Debt | -1.53B -1.36B -1.26B -1.15B -2.16B -145B -2.19B -15.16B -5.96B -75.85B -5.74B -5.62B -242B | -1.17B -1.04B -967M -880M -1.65B -111B -1.68B -11.6B -4.56B -58.05B -4.4B -4.3B -186B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-19 | US$50.04 | +1.60% | 1,176,820 |
| 26-10-16 | US$49.25 | -4.41% | 1,524,985 |
| 26-10-15 | US$51.52 | +2.59% | 1,352,945 |
| 26-10-14 | US$50.22 | +0.24% | 1,707,556 |
| 26-10-13 | US$50.10 | -2.81% | 1,342,658 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRSP Stock
Select your edition
All financial news and data tailored to specific country editions
